[Chinese guidelines for the diagnosis and treatment of hereditary hemochromatosis].

{"title":"[Chinese guidelines for the diagnosis and treatment of hereditary hemochromatosis].","authors":"","doi":"10.3760/cma.j.cn501113-20240712-00319","DOIUrl":null,"url":null,"abstract":"<p><p>Hereditary hemochromatosis is an iron overload disease caused by mutations in iron-regulating genes, resulting in excessive iron deposition in organs such as the liver, heart, skin, pancreas, and gonads, leading to corresponding multi-system damage. This condition is relatively common in European and American populations, primarily caused by mutations in the HFE gene; however, it is rare in China and other Asian countries, almost exclusively due to mutations in non-HFE genes. Clinical features include unexplained chronic hepatitis or cirrhosis, accompanied by elevated serum ferritin and/or increased transferrin saturation. MRI shows iron deposition in the liver, liver biopsy reveals iron accumulation in hepatocytes, and genetic testing facilitate the diagnosis of this disease. Repeated phlebotomy is the first-line therapy for this condition. For those who cannot tolerate phlebotomy, iron chelation therapy may be used, and patients who progress to end-stage liver disease will require liver transplantation. To assist clinicians in making informed decisions on the diagnosis and treatment of hereditary hemochromatosis, the Chinese Society of Hepatology, Chinese Medical Association has invited experts from clinical medicine, molecular genetics, pathology, imaging, and methodology to systematically summarize the advancement in this field and collaboratively develop the current guidelines.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 9","pages":"787-798"},"PeriodicalIF":0.0000,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中华肝脏病杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/cma.j.cn501113-20240712-00319","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Hereditary hemochromatosis is an iron overload disease caused by mutations in iron-regulating genes, resulting in excessive iron deposition in organs such as the liver, heart, skin, pancreas, and gonads, leading to corresponding multi-system damage. This condition is relatively common in European and American populations, primarily caused by mutations in the HFE gene; however, it is rare in China and other Asian countries, almost exclusively due to mutations in non-HFE genes. Clinical features include unexplained chronic hepatitis or cirrhosis, accompanied by elevated serum ferritin and/or increased transferrin saturation. MRI shows iron deposition in the liver, liver biopsy reveals iron accumulation in hepatocytes, and genetic testing facilitate the diagnosis of this disease. Repeated phlebotomy is the first-line therapy for this condition. For those who cannot tolerate phlebotomy, iron chelation therapy may be used, and patients who progress to end-stage liver disease will require liver transplantation. To assist clinicians in making informed decisions on the diagnosis and treatment of hereditary hemochromatosis, the Chinese Society of Hepatology, Chinese Medical Association has invited experts from clinical medicine, molecular genetics, pathology, imaging, and methodology to systematically summarize the advancement in this field and collaboratively develop the current guidelines.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
[中国遗传性血色病诊断和治疗指南]。
遗传性血色病是一种铁超载疾病,由铁调节基因突变引起,导致肝脏、心脏、皮肤、胰腺和性腺等器官中铁过度沉积,引起相应的多系统损害。这种疾病在欧美人群中比较常见,主要是由 HFE 基因突变引起的;但在中国和其他亚洲国家却很少见,几乎完全是由非 HFE 基因突变引起的。临床特征包括原因不明的慢性肝炎或肝硬化,伴有血清铁蛋白升高和/或转铁蛋白饱和度升高。核磁共振成像显示肝脏内有铁沉积,肝脏活检显示肝细胞内有铁积聚,基因检测有助于该病的诊断。反复抽血是治疗这种疾病的一线疗法。对于不能耐受抽血疗法的患者,可采用铁螯合疗法,进展到终末期肝病的患者则需要进行肝移植。为了帮助临床医生对遗传性血色病的诊断和治疗做出明智的决定,中华医学会肝病学分会邀请了来自临床医学、分子遗传学、病理学、影像学和方法学等领域的专家,系统总结了该领域的进展,并共同制定了目前的指南。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
中华肝脏病杂志
中华肝脏病杂志 Medicine-Medicine (all)
CiteScore
1.20
自引率
0.00%
发文量
7574
期刊介绍:
期刊最新文献
[The Research and Application Progress of Heterologous Liver Transplantation]. [The nomogram model and its value study of Gd-EOB-DTPA enhanced MRI for preoperative diagnosis of proliferative hepatocellular carcinoma]. [Excerpt from the 2023 European Association for the Study of the Liver practice guidelines: prevention, diagnosis, and treatment of intrahepatic cholangiocarcinoma]. [Rifaximin curative effect and mechanism on monocrotaline-induced hepatic sinusoidal obstruction syndrome in mice]. [A case of Wilson's disease misdiagnosed as autoimmune hepatitis and literature review].
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1